Ali Al-Otaibi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ali Al-Otaibi has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Fahad A. Bashiri
Pediatric Neurology Division, Department of Pediatrics, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
3 shared publications Ali Mir
2 shared publications- Abdulaziz Alghamdi
Division of Pediatric Neurology, Department of Pediatrics, Prince Sultan Military Medical City, PO Box 7889, Riyadh 11159, Saudi Arabia
1 shared publication - Abdulaziz K. Alotaibi1 shared publication
- Abdullah Aldakhil
Itkan Health Consulting Group, Al Olaya, Riyadh 12221, Saudi Arabia
1 shared publication Abeer Matar
Department of Pediatrics, Maternity and Children Hospital, Makkah, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Evaluating the pediatric neurology training curriculum in SCFHS-accredited programs: a multi-institutional survey study
Background: Pediatric neurology training must evolve to meet increasing clinical complexity and rapid advances in neuroscience while maintaining high standards of family-centered care. In Saudi Arabia, structured residency programs have expanded under national accreditation frameworks; however, systematic evaluations of curriculum adequacy from the faculty perspective remain limited. This study aimed to comprehensively evaluate the pediatric neurology training curriculum within the Saudi Commission for Health Specialties (SCFHS)-accredited training system (including programs in Saudi Arabia and the United Arab Emirates [UAE]) from the faculty perspective, identifying strengths, gaps, and differences between program directors (PDs) and non-director faculty. Methods: We conducted a multi-institutional cross-sectional study between September and December 2025 targeting pediatric neurology faculty, including PDs, deputy directors, core faculty, and clinical staff involved in resident education. A validated 47-item questionnaire assessed satisfaction across six core curriculum components (educational resources, graduate autonomy and safety, clinical knowledge, clinical–academic balance, research opportunities, and professionalism), identified priority training gaps, and collected qualitative recommendations. Quantitative data were analyzed using descriptive statistics, non-parametric comparisons, correlation analysis, and exploratory multivariable linear regression. Open-ended responses underwent inductive thematic analysis. Results: Forty-three consultants participated, including nine PDs. Overall satisfaction was moderate, with the highest ratings for resident professionalism (mean 3.8/5) and the lowest for clinical–academic balance (2.8/5) and research opportunities (2.9/5). Genetics and hereditary diseases (74%), neuroimmunology (70%), and neurodevelopmental disorders (63%) were the most frequently cited domains requiring greater emphasis. PDs reported significantly lower overall satisfaction than non-directors (β = −0.37, p = 0.02), particularly regarding academic time and research infrastructure. Satisfaction with educational resources strongly correlated with perceived research opportunities (ρ = 0.58, p < 0.001). Qualitative themes highlighted excessive service demands, insufficient protected academic time, limited research mentorship, and the need for structured training in rapidly evolving subspecialties. Conclusion: Pediatric neurology training in the region demonstrates strong clinical and professional foundations but is constrained by systemic challenges in academic balance, research support, and subspecialty preparedness. These perception-based findings suggest that PDs’ heightened concerns may inform future curriculum development. Potential areas for consideration include protected academic time, enhanced research infrastructure, and nationally coordinated curricula in high-priority domains. However, these are exploratory implications requiring further evaluation before implementation.
- 17 July 2026
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Open AccessEvaluating the pediatric neurology training curriculum in SCFHS-accredited programs: a multi-institutional survey study
Background: Pediatric neurology training must evolve to meet increasing clinical complexity and rapid advances in neuroscience while maintaining high standards of family-centered care. In Saudi Arabia, structured residency programs have expanded under national accreditation frameworks; however, systematic evaluations of curriculum adequacy from the faculty perspective remain limited. This study aimed to comprehensively evaluate the pediatric neurology training curriculum within the Saudi Commission for Health Specialties (SCFHS)-accredited training system (including programs in Saudi Arabia and the United Arab Emirates [UAE]) from the faculty perspective, identifying strengths, gaps, and differences between program directors (PDs) and non-director faculty. Methods: We conducted a multi-institutional cross-sectional study between September and December 2025 targeting pediatric neurology faculty, including PDs, deputy directors, core faculty, and clinical staff involved in resident education. A validated 47-item questionnaire assessed satisfaction across six core curriculum components (educational resources, graduate autonomy and safety, clinical knowledge, clinical–academic balance, research opportunities, and professionalism), identified priority training gaps, and collected qualitative recommendations. Quantitative data were analyzed using descriptive statistics, non-parametric comparisons, correlation analysis, and exploratory multivariable linear regression. Open-ended responses underwent inductive thematic analysis. Results: Forty-three consultants participated, including nine PDs. Overall satisfaction was moderate, with the highest ratings for resident professionalism (mean 3.8/5) and the lowest for clinical–academic balance (2.8/5) and research opportunities (2.9/5). Genetics and hereditary diseases (74%), neuroimmunology (70%), and neurodevelopmental disorders (63%) were the most frequently cited domains requiring greater emphasis. PDs reported significantly lower overall satisfaction than non-directors (β = −0.37, p = 0.02), particularly regarding academic time and research infrastructure. Satisfaction with educational resources strongly correlated with perceived research opportunities (ρ = 0.58, p < 0.001). Qualitative themes highlighted excessive service demands, insufficient protected academic time, limited research mentorship, and the need for structured training in rapidly evolving subspecialties. Conclusion: Pediatric neurology training in the region demonstrates strong clinical and professional foundations but is constrained by systemic challenges in academic balance, research support, and subspecialty preparedness. These perception-based findings suggest that PDs’ heightened concerns may inform future curriculum development. Potential areas for consideration include protected academic time, enhanced research infrastructure, and nationally coordinated curricula in high-priority domains. However, these are exploratory implications requiring further evaluation before implementation.
- Open Access
- 16 July 2025
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 30 (3) , 209-215
Stiripentol safety profile and efficacy in cases of SCN1A-related Dravet syndrome, multi-center experience, Saudi Arabia
Objectives: To evaluate the effectiveness and safety of Stiripentol (STP) in individuals with Dravet syndrome resulting from SCN1A gene mutation Methods: A retrospective study with a descriptive focus was carried out in 2023, involving 44 patients diagnosed with Dravet Syndrome, with data collected by chart review and interviews of caregivers based on a pre-structured data extraction sheet. Data included age of seizure onset, SCN1A gene variant, duration of seizures before STP initiation, age at the time of starting STP administration, change in seizure frequency or duration after STP initiation, and at 6 months following initiation, and concomitant anti-seizure medication. Results: 25 patients experienced a significant reduction in the frequency of their seizures, while 12 showed a mild to moderate reduction. Almost all patients taking Stiripentol concomitant with Valproate and Clobazam had marked seizure reduction. Adverse reactions to Stiripentol were observed in 34 patients, but none were serious. Somnolence was the highest reported (20 patients), followed by behavioral changes, agitation, irritability, and hyperactivity (18 patients) Conclusion: Our study showed that over half of our patients with Dravet on Stiripentol had a marked reduction in seizure frequency and duration. The study revealed no serious adverse events. Minor adverse events included somnolence and behavioral changes.
- 16 July 2025
- Published by Armed Forces Medical Services in Neurosciences
- Vol. 30 (3) , 209-215
Open AccessStiripentol safety profile and efficacy in cases of SCN1A-related Dravet syndrome, multi-center experience, Saudi Arabia
Objectives: To evaluate the effectiveness and safety of Stiripentol (STP) in individuals with Dravet syndrome resulting from SCN1A gene mutation Methods: A retrospective study with a descriptive focus was carried out in 2023, involving 44 patients diagnosed with Dravet Syndrome, with data collected by chart review and interviews of caregivers based on a pre-structured data extraction sheet. Data included age of seizure onset, SCN1A gene variant, duration of seizures before STP initiation, age at the time of starting STP administration, change in seizure frequency or duration after STP initiation, and at 6 months following initiation, and concomitant anti-seizure medication. Results: 25 patients experienced a significant reduction in the frequency of their seizures, while 12 showed a mild to moderate reduction. Almost all patients taking Stiripentol concomitant with Valproate and Clobazam had marked seizure reduction. Adverse reactions to Stiripentol were observed in 34 patients, but none were serious. Somnolence was the highest reported (20 patients), followed by behavioral changes, agitation, irritability, and hyperactivity (18 patients) Conclusion: Our study showed that over half of our patients with Dravet on Stiripentol had a marked reduction in seizure frequency and duration. The study revealed no serious adverse events. Minor adverse events included somnolence and behavioral changes.
- Open Access
- 23 February 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 117, 174-182
Diagnosis and management of infantile epileptic spasms syndrome (IESS) in Gulf Cooperation Council (GCC) countries: Expert consensus statement
- 23 February 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 117, 174-182
Open AccessDiagnosis and management of infantile epileptic spasms syndrome (IESS) in Gulf Cooperation Council (GCC) countries: Expert consensus statement
- Open Access
- 5 July 2023
- Published by Elsevier in Brain Disorders
- Vol. 11
Paroxysmal nonepileptic events in children and adolescents admitted to the epilepsy monitoring unit: A retrospective study
- 5 July 2023
- Published by Elsevier in Brain Disorders
- Vol. 11
Open AccessParoxysmal nonepileptic events in children and adolescents admitted to the epilepsy monitoring unit: A retrospective study
- Open Access
- 1 January 2019
- Published by Medknow in Journal of Pediatric Neurosciences
- Vol. 14 (4) , 180-185
Anti-N-methyl-d-aspartate receptor encephalitis: A case series and review of the literature
Anti-NMDAR (N-methyl-d-aspartate receptor) encephalitis is a potentially severe form of encephalitis associated with antibodies against NR1 and NR2 subunits of the NMDAR. Anti-NMDAR encephalitis is a treatable cause of encephalitis. An underlying tumor should be actively looked for as this is also considered to be a paraneoplastic syndrome. We report two children with anti-NMDAR encephalitis with a literature review of current evidence in diagnosing and managing this rare condition. Resection of the tumor, glucocorticoids, intravenous immunoglobulin, and plasma exchange often result in improvement, usually within four weeks. Outcome corresponds with the rapidity of commencing appropriate treatment.
- 1 January 2019
- Published by Medknow in Journal of Pediatric Neurosciences
- Vol. 14 (4) , 180-185
Open AccessAnti-N-methyl-d-aspartate receptor encephalitis: A case series and review of the literature
Anti-NMDAR (N-methyl-d-aspartate receptor) encephalitis is a potentially severe form of encephalitis associated with antibodies against NR1 and NR2 subunits of the NMDAR. Anti-NMDAR encephalitis is a treatable cause of encephalitis. An underlying tumor should be actively looked for as this is also considered to be a paraneoplastic syndrome. We report two children with anti-NMDAR encephalitis with a literature review of current evidence in diagnosing and managing this rare condition. Resection of the tumor, glucocorticoids, intravenous immunoglobulin, and plasma exchange often result in improvement, usually within four weeks. Outcome corresponds with the rapidity of commencing appropriate treatment.
- 30 November 2018
- Published by Discover STM Publishing Ltd. in Journal of Biochemical and Clinical Genetics
- Vol. 1 (2) , 98-101
ISCA2 Related Mitochondrial Disorder: A distinct cause of Infantile Leukodystrophy
Introduction: Iron-Sulfur Cluster (ISC) biogenesis is a vital cellular process in the mitochondria. It is required to produce various ISC-containing proteins which are present in the nucleus, mitochondria, and cytosol. ISC proteins are responsible for essential functions such as glycine cleavage and the formation of lipoic acid. ISCA2 encodes an A-type ISC protein involved in the assembly of mitochondrial iron-sulfur cluster (4Fe- 4S) which is important for electron transfer and mitochondrial function. ISCA2 related Mitochondrial Disorder (IRMD) is a severe disorder of systemic energy metabolism, characterized by weakness, respiratory failure, lack of neurological development, lactic acidosis, hyperglycinemia and early death. ISCA2 gene is located on Chromosome 14q24.3 and has autosomal recessive inheritance. Objective: In this report, we present the clinical and radiological features a subject homozygous for the common founder pathogenic variant; c.229G>A; p.Gly77Ser. Conclusion: IRMD presents with infantile onset triad of progressive neurodevelopmental regression, nystagmus and optic atrophy. It is a rapidly progressive condition with death usually in first two years of life. It should be considered in infantile onset leukodystrophy. Future studies are needed to understand the role of ISCA2 gene, the effect of its mutation, and any targets for future treatment strategies.
- 30 November 2018
- Published by Discover STM Publishing Ltd. in Journal of Biochemical and Clinical Genetics
- Vol. 1 (2) , 98-101
ISCA2 Related Mitochondrial Disorder: A distinct cause of Infantile Leukodystrophy
Introduction: Iron-Sulfur Cluster (ISC) biogenesis is a vital cellular process in the mitochondria. It is required to produce various ISC-containing proteins which are present in the nucleus, mitochondria, and cytosol. ISC proteins are responsible for essential functions such as glycine cleavage and the formation of lipoic acid. ISCA2 encodes an A-type ISC protein involved in the assembly of mitochondrial iron-sulfur cluster (4Fe- 4S) which is important for electron transfer and mitochondrial function. ISCA2 related Mitochondrial Disorder (IRMD) is a severe disorder of systemic energy metabolism, characterized by weakness, respiratory failure, lack of neurological development, lactic acidosis, hyperglycinemia and early death. ISCA2 gene is located on Chromosome 14q24.3 and has autosomal recessive inheritance. Objective: In this report, we present the clinical and radiological features a subject homozygous for the common founder pathogenic variant; c.229G>A; p.Gly77Ser. Conclusion: IRMD presents with infantile onset triad of progressive neurodevelopmental regression, nystagmus and optic atrophy. It is a rapidly progressive condition with death usually in first two years of life. It should be considered in infantile onset leukodystrophy. Future studies are needed to understand the role of ISCA2 gene, the effect of its mutation, and any targets for future treatment strategies.
- Open Access
Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study
Summary: Purpose: To examine patterns of use, efficacy, and safety of intravenous ketamine for the treatment of refractory status epilepticus (RSE).Methods: Multicenter retrospective review of medical records and electroencephalography (EEG) reports in 10 academic medical centers in North America and Europe, including 58 subjects, representing 60 episodes of RSE that were identified between 1999 and 2012. Seven episodes occurred after anoxic brain injury.Key Findings: Permanent control of RSE was achieved in 57% (34 of 60) of episodes. Ketamine was felt to have contributed to permanent control (“possible” or “likely” responses) in 32% (19 of 60) including seven (12%) in which ketamine was the last drug added (likely responses). Four of the seven likely responses, but none of the 12 possible ones, occurred in patients with postanoxic brain injury. No likely responses were observed when infusion rates were lower than 0.9 mg/kg/h, when ketamine was introduced at least 8 days after SE onset, or after failure of seven or more drugs. Ketamine was discontinued due to possible adverse events in five patients. Complications were mostly attributed to concurrent drugs, especially other anesthetics. Mortality rate was 43% (26 of 60), but was lower when SE was controlled within 24 h of ketamine initiation (16% vs. 56%, p = 0.0047).Significance: Ketamine appears to be a relatively effective and safe drug for the treatment of RSE. This retrospective series provides preliminary data on effective dose and appropriate time of intervention to aid in the design of a prospective trial to further define the role of ketamine in the treatment of RSE.
Open AccessIntravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study
Summary: Purpose: To examine patterns of use, efficacy, and safety of intravenous ketamine for the treatment of refractory status epilepticus (RSE).Methods: Multicenter retrospective review of medical records and electroencephalography (EEG) reports in 10 academic medical centers in North America and Europe, including 58 subjects, representing 60 episodes of RSE that were identified between 1999 and 2012. Seven episodes occurred after anoxic brain injury.Key Findings: Permanent control of RSE was achieved in 57% (34 of 60) of episodes. Ketamine was felt to have contributed to permanent control (“possible” or “likely” responses) in 32% (19 of 60) including seven (12%) in which ketamine was the last drug added (likely responses). Four of the seven likely responses, but none of the 12 possible ones, occurred in patients with postanoxic brain injury. No likely responses were observed when infusion rates were lower than 0.9 mg/kg/h, when ketamine was introduced at least 8 days after SE onset, or after failure of seven or more drugs. Ketamine was discontinued due to possible adverse events in five patients. Complications were mostly attributed to concurrent drugs, especially other anesthetics. Mortality rate was 43% (26 of 60), but was lower when SE was controlled within 24 h of ketamine initiation (16% vs. 56%, p = 0.0047).Significance: Ketamine appears to be a relatively effective and safe drug for the treatment of RSE. This retrospective series provides preliminary data on effective dose and appropriate time of intervention to aid in the design of a prospective trial to further define the role of ketamine in the treatment of RSE.